Shares of Endo Pharmaceuticals Holdings Inc. climbed more than 6 percent Thursday in pre-market trading, a day after the drug company said it received U.S. approval to market Fortesta gel to treat low testosterone in men.
All News, Video and Posts related to SECTOR: Health Care
Popular Posts:
- WSJ: Genzyme, Sanofi discuss higher buyout price
- Depomed 3Q profit rises
- Alere board authorizes $50M share repurchase
- WSJ: Genzyme, Sanofi discuss higher buyout price
- WSJ: Genzyme, Sanofi discuss higher buyout price